Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TYK Medicines, Inc
浙江同源康醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON COMMERCIALISATION OF CORE PRODUCT KARDORISSO (TY-9591)

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

As announced by the Company on August 27, 2026, Kardorisso (TY-9591), a new drug self-developed by the Company, has obtained conditional approval for marketing granted by the National Medical Products Administration of China for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutation.

It is expected that the production of the first batch of Kardorisso (TY-9591) will be completed on November 18, 2026. It is expected that by the end of November 2026, the first batch of Kardorisso (TY-9591) products will be officially shipped through commercial channels to the first-tier distributor(s) designated by Qilu (as defined below), and Qilu (as defined below) is expected to launch academic promotion activities on November 13, 2026, marking the official commencement of commercial sales and prescription of Kardorisso (TY-9591) in the PRC. Going forward, the Company will continue to work with Qilu Pharmaceutical (Hainan) Co., Ltd. ("**Qilu**") to commercialize Kardorisso (TY-9591) in accordance with the License and Collaboration Agreement and Supplies and Commercialization Agreement as outlined in the Company's announcements dated July 21, 2026 and November 11, 2026.

About Kardorisso (TY-9591)

Kardorisso (TY-9591) is a highly selective, irreversible EGFR-TKI self-developed by the Group. Benefiting from its favourable pharmacokinetic characteristics, the drug can significantly reduce the formation of toxic metabolites, thereby demonstrating strong therapeutic potential while maintaining safety. Kardorisso (TY-9591) has demonstrated compelling efficacy and best-in-class potential in multiple clinical studies, particularly in patients with brain metastases from EGFR-mutant NSCLC and patients harbouring the EGFR L858R mutation, in whom its efficacy was especially pronounced. In addition to monotherapy, the Company is also rapidly advancing a number of combination therapy studies. Among them, Kardorisso (TY-9591) in combination with chemotherapy has reached the preparatory stage for the initiation of a registrational clinical trial. Kardorisso (TY-9591) is expected to provide a superior treatment option for a broad population of patients with EGFR-mutant NSCLC and further address unmet clinical needs.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize Kardorisso (TY-9591) successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, November 11, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.